Personalized daily doses of imatinib by therapeutic drug monitoring increase the rates of molecular responses in patients with chronic myeloid leukemia. Final results of the randomized OPTIM imatinib study.
Rousselot P, Johnson-Ansah H, Huguet F, et al. Blood. 2015;126.
In this study sixty-five percent of CML patients had imatinib levels below the established therapeutic threshold (Cmin or Ctrough). Measuring patient’s Cmin and adjusting dosage resulted in significantly higher imatinib plasma levels and molecular responses (63%) compared to standard management for patients below the Cmin target (37%). The patients receiving TDM achieved similar (not statistically different) molecular responses as patients in the therapeutic range.